Search Within

Carlyn Rose Tan

Formats
  1. Meeting Abstract (104)
  2. Journal Article (25)
  3. Research Letter (8)
  4. Correspondence (4)
  5. Review (3)
Groups
  1. Hematologic Malignancies, Division of (144)
  2. Department of Medicine (126)
  3. Center for Hematologic Malignancies (125)
  4. Myeloma (123)
  5. Survivorship Research (123)
  6. CTCR Scholars (122)

More Groups

People
  1. Alexander Lesokhin (121)
  2. Sham Mailankody (121)
  3. Urvi Shah (121)
  4. Malin Hultcrantz (120)
  5. Hani Hassoun (119)
  6. Neha Korde (119)

More People

Years
  1. 2025 (10)
  2. 2024 (44)
  3. 2023 (41)
  4. 2022 (29)
  5. 2021 (13)
  6. 2020 (7)
Publications
  1. Blood (54)
  2. Clinical Lymphoma, Myeloma and Leukemia (41)
  3. Journal of Clinical Oncology (9)
  4. Blood Cancer Journal (7)
  5. Blood Advances (5)
  6. American Journal of Hematology (4)

More Publications

Publishers
  1. American Society of Hematology (59)
  2. Elsevier Inc. (44)
  3. American Society of Clinical Oncology (9)
  4. Nature Publishing Group (9)
  5. John Wiley & Sons, Inc. (4)
  6. Taylor & Francis Group (3)

More Publishers

Results (144)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of the safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment
    Meeting Abstract

    Terpos, E.; Ntanasis-Stathopoulos, I.; Kyriakou, C.; Tan, C.; Abildgaard, N.; Delforge, M.; Fantl, D.; Usmani, S.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real world experience of talquetamab in relapsed refractory myeloma, first report from the IMWG Consortium
    Meeting Abstract

    Janakiram, M.; Tan, C.; Popat, R.; Kastritis, E.; Martínez-Lopez, J.; Shekarkhand, T.; Bansal, R.; De Menezes Silva Corraes, A.; de la puerta, M. C.; Sáez Marín, A. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save